Pfizer’s Prevenar 20 Receives EC’s Approval for the Protection Against Pneumococcal Disease in Pediatric Population
Shots:
- Pfizer’s 20-valent pneumococcal conjugate vaccine, Prevenar 20, has received EC's marketing authorization valid in the EU region along with Iceland, Lichtenstein & Norway to prevent invasive disease, pneumonia & acute otitis media caused by Streptococcus pneumoniae in the pediatric population (6wks. to <18yrs.)
- The approval was supported by the data from a series of P-III pediatric studies (NCT04546425, NCT04382326, NCT04379713, NCT04642079) establishing the safety, tolerability & immunogenicity of the vaccine in infants (n=4,700), toddlers (n= 800) & children of all ages
- The authorization was followed by the CHMP’s positive opinion. Further regulatory applications for the vaccine have been submitted globally
Ref: Pfizer | Image: Pfizer
Related News:- Pfizer Reports P-III Study Results of Adcetris for Treating Diffuse Large B-cell Lymphoma (DLBCL)
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
